What's new

Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Status: Opinion

Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Status: Opinion

Feb 9, 2025 - 21:46
 0
Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Status: Opinion
Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Status: Opinion
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, ...

Next Article

EMA Open Door Day, European Medicines Agency, Amsterdam, the Netherlands, from 9...

Related Posts

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Izelvay, avacincaptad pegol, Status: Application withdrawn

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Spexotras, trametinib, Date of authorisation: 05/01/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025  0